BRAF and melanoma: The primary cell line—WM793 and metastatic one—Lu1205, as in the majority of melanoma cases, carry a mutation in the B-RAF kinase (V600E), while the WM115 (primary) and WM266-4 (metastatic) cell lines have the V600D mutation, and all tested melanoma cell lines seem to be very sensitive to treatment with B-RAF inhibitors PLX-4032.